In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

If you have IgA nephropathy (IgAN), you’ve likely heard about the importance of protecting your kidneys and slowing down the disease. In IgAN, immunoglobulin A (IgA) antibodies accumulate in the ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

SGLT2i and GLP-1RA are associated with lower risks of hyperkalemia compared with DPP4i in patients with CKD and type 2 diabetes. Hyperkalemia risks in patients with chronic kidney disease (CKD) and ...